Most importantly, all co-treatments with the repositioned compounds, except for DIF, were found in the same cluster with the SIR + FFAs and RSV + FFAs, thus highlighting GAL's, FEN's, and PRA's potential in ameliorating in vitro steatosis at the pathway level. The gene discussed is S100A6; the disease is steatosis.